Compare Revvity Inc (RVTY) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Boston Beer Company Inc — how do they compare? Revvity Inc trades at $115.76 (market cap $12.94B), while Boston Beer Company Inc trades at $177.2 (market cap $1.86B). The key difference: Revvity Inc is far larger — about 7× Boston Beer Company Inc's market cap, and Revvity Inc pays a 0.24% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| RVTY | SAM | |
|---|---|---|
Market Cap | $12.94B | $1.86B |
Sector | Technology | Consumer Staples |
52-Week High | $117.75 | $260.05 |
52-Week Low | $82.26 | $161.08 |
Enterprise Value | $15.26B | $1.63B |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $114.66, up 0.37% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a 54.98% gross margin and $241.20M net income for 2025, supported by positive news including product launches and raised 2026 guidance. Analyst consensus is a buy with a $120.50 price target, indicating potential upside from current levels.
Outlook remains positive due to consistent earnings outperformance and innovation in diagnostics, but risks include high P/E valuation and competitive pressures. Investors may find opportunity in sustained margin strength and AI integration, though macroeconomic sensitivity warrants caution.
The Boston Beer Company (SAM) trades at $186.61, up 1.94% on the day, with a bullish technical signal driven by moving averages. The stock shows mixed fundamentals; while the P/E ratio of 22.66 and P/S of 0.99 suggest reasonable valuation, recent quarterly earnings have missed expectations, and the company faces volume declines in core brands. Positive cash flow and innovation in ready-to-drink products provide some offset. Analyst sentiment is cautious, with a consensus price target of $207.33 but a majority hold rating.
Outlook: Upside exists if new product growth accelerates and margins improve, but risks from weak demand and competitive pressure persist. The stock's trajectory hinges on reversing volume trends and achieving future earnings targets, making it a hold for now with watchful optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
